In their study, the authors reported that treatment of murine meningiomas using anti-CSF1/CSF1R monoclonal antibodies, in contrast to anti-PD1 therapy, was efficacious and inhibited tumor growth [49]. The gene discussed is CSF1; the disease is meningioma.